Mirabegron Tablet, Extended Release
Product Images NDC 70771-1752
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Mirabegron (NDC 70771-1752). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 02)
Figure 2 (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 03)
Figure 3 (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 04)
Figure 4 (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 05)
Figure 5 (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 06)
Figure 6 (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 07)
Figure 7 (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 08)
Figure 8 (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 09)
Mirabegron Extended-release Tablets, 25mg (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 10)
Mirabegron Extended-release Tablets, 50mg (2c538bd8 5345 4a9f 8370 B5b81e9edf3a 11)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.